Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

Medtronic (NYSE: MDT) today announced the launch of its Stedi extra support guidewire for use with its Evolut TAVR platform.

Edwards Lifesciences Corp. (($EW)) announced an update on their ongoing clinical study. Study Overview: Edwards Lifesciences Corp. is conducting ...

The results underscore the need to perform CT imaging when deciding between procedures in patients with aortic stenosis.

LONDON -- It was best that people interrupt their oral anticoagulation (OAC) therapy around the time they get transcatheter aortic valve replacement (TAVR, also TAVI), the POPular PAUSE TAVI trial ...

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...

PARIS — Despite some potential advantages, transcatheter aortic valve implantation (TAVI) failed to meet the primary prespecified threshold for noninferiority to surgical aortic valve replacement in ...

Investing.com -- Edwards Lifesciences (NYSE:EW) stock rose 4.5% following the presentation of new data showing long-term benefits and valve performance of its SAPIEN 3 TAVR.

Saint Alphonsus in Boise earned a three-star TAVR ranking from STS and ACC, placing it among the nation’s top heart programs ...